Taken together, the preclinical evidence presented here hints at a potential therapeutic synergism of KRAS inhibition by means of AMG510 (Sotorasib) or BI-3406 in combination with MEK inhibition by Binimetinib and concomitant irradiation in KRAS mutant pancreatic cancer. This evidence concerns the gene MAP2K7 and pancreatic neoplasm.